Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 452 for:    DICLOFENAC

Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02495831
Recruitment Status : Completed
First Posted : July 13, 2015
Results First Posted : April 15, 2016
Last Update Posted : April 15, 2016
Sponsor:
Collaborator:
Cross Research S.A.
Information provided by (Responsible Party):
Zambon SpA

Brief Summary:
To evaluate if a single dose of safinamide 200 mg has an effect on the pharmacokinetics of diclofenamic acid, concomitantly administered as a single 50 mg diclofenac sodium dose, with respect to 50 mg diclofenac sodium administered alone.

Condition or disease Intervention/treatment Phase
Healthy Drug: Diclofenac sodium Drug: Diclofenac sodium and safinamide Phase 1

Detailed Description:

According to Xadago™ SmPC, safinamide may transiently inhibit BCRP, therefore a time interval of 5 h should be kept between dosing of safinamide and medicinal products that are BCRP substrates with a Tmax ≤2 h (e.g. diclofenac, pitavastatin, pravastatin, ciprofloxacin, methotrexate, topotecan or glyburide).

Following a specific request of EMA CHMP, the present interaction study in healthy male and female volunteers was conducted to determine if co-administration of safinamide with a BCRP substrate alters plasma exposure of the BCRP substrate in vivo.

Diclofenac was chosen among the other BCRP substrates considering its large use in the general population. Diclofenac in fact is an important analgesic and anti-inflammatory drug, widely used for the treatment of postoperative pain, rheumatoid arthritis, and chronic pain. Consequently, diclofenac is often used in combination regimens and undesirable drug-drug interactions may occur.

Voltaren®, 50 mg soluble tablets, was selected among other possible diclofenac products because with this formulation peak concentration of diclofenamic acid is achieved at approximately 1 h, i.e. in less than 2 h.

The present interaction study was designed in agreement with the FDA Guideline on Drug Interaction studies, taking also in consideration the EMA guideline on the Investigation of drug interactions.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers
Study Start Date : May 2015
Actual Primary Completion Date : May 2015
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drug Reactions

Arm Intervention/treatment
Experimental: Diclofenac sodium
Diclofenac sodium 50 mg oral tablets, single dose
Drug: Diclofenac sodium
Diclofenac sodium 50 mg single dose
Other Name: Voltaren

Active Comparator: Diclofenac sodium and safinamide
Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose
Drug: Diclofenac sodium and safinamide
Diclofenac 50 mg single dose and safinamide 200 mg single dose
Other Name: Voltaren and Xadago




Primary Outcome Measures :
  1. To Evaluate Plasma Diclofenamic Acid Extent of Exposure Reported as Plasma AUC After Single Administration of 50 mg Diclofenac Sodium, With and Without Co-administration of a Single 200 mg Dose of Safinamide. [ Time Frame: 24 hours ]
    Plasma diclofenamic acid AUC0-t after T2 single dose, with and without T1 co-administration. To measure AUC plasma samples were taken by the participants at different time points, and the concentrations of diclofenac and safinamide were measured. AUC0-t is the area under the concentration-time curve from administration to the last observed concentration time t; PK parameters AUC0-t were analysed using analysis of variance (ANOVA). Before analysis, the data were transformed using a neperian logarithmic transformation. ANOVA was performed taking into account treatment, period, sequence and subject (sequence) as fixed effects with a variance components structure of the covariance matrix.


Secondary Outcome Measures :
  1. Evaluate Diclofenac Rate of Absorption Reported as Plasma Cmax After Single Administration of 50 mg Diclofenac With and Without 200 mg of Safinamide. [ Time Frame: 24 hours ]
    Cmax, of plasma diclofenamic acid after T2 single dose, with and without T1 co-administration. The parametric point estimators (PE) for the ratios of T2 treatment with T1 co-administration / T2 treatment without T1 co-administration for the PK parameters under consideration, and the two-sided 90% confidence interval (CI), were calculated using the adjusted least squares means (LSMEANS) from the ANOVA. LSmeans differences obtained in the log scale for Cmax were back-transformed to obtain the PE (i.e. geometric mean ratio) and the two-sided 90% CI as percentages.

  2. Tmax and T1/2 [ Time Frame: 24 hours ]
  3. Lamda z [ Time Frame: 24 hours ]
  4. Relative Bioavailability (Frel) [ Time Frame: 24 hours ]
    calculated as ratio between AUC0-t (test) / AUC0-t (reference)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Signed written informed consent before inclusion in the study
  2. Males and females, 25-55 years old
  3. Body Mass Index (BMI): 18.5-30 kg/m2
  4. Systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm
  5. Ability to comprehend the full nature and purpose of the study
  6. Females of child-bearing potential must use at least one of the following :

A non-hormonal intrauterine device or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit A male sexual partner who agreed to use a male condom with spermicide A sterile sexual partner Female participants of non-child-bearing potential or in post-menopausal status for at least 1 year were admitted.

Exclusion Criteria:

  1. Contraindications to MAO-B inhibitors, antiepileptic drugs, or to any NSAIDs
  2. Clinically significant abnormalities in ECG
  3. Clinically significant abnormal physical findings
  4. Clinically significant abnormal laboratory values
  5. Hypersensitivity or history of anaphylaxis to drugs or allergic reactions in general
  6. Significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases
  7. Medications, including over the counter medications and herbal remedies, NSAID or anticoagulant use for 2 weeks before and during the entire study; morphine or other similar opioids, SSRIs, SNRIs, tri- or tetracyclic antidepressant, tramadol, pethidine, dextromethorphan, MAO inhibitors, meperidine derivatives and antiepileptic drugs, medicinal products that are BCRP substrates, any known enzyme inhibiting or inducing agent within 4 weeks preceding the screening visit.
  8. Participation in the evaluation of any investigational product for 3 months before the study.
  9. Blood donations for 3 months before the study
  10. History of drug, alcohol, caffeine or tobacco abuse
  11. Positive drug test at screening or day -1
  12. Positive alcohol breath test at day -1
  13. Abnormal diets or substantial changes in eating habits in the 4 weeks before the study; vegetarians
  14. Positive or missing pregnancy test at screening or day -1, pregnant or lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02495831


Locations
Layout table for location information
Switzerland
Cross Research SA, Phase I Unit
Arzo, Ticino, Switzerland, 6864
Sponsors and Collaborators
Zambon SpA
Cross Research S.A.
Investigators
Layout table for investigator information
Principal Investigator: Milko Radicioni, MD Cross Research SA

Layout table for additonal information
Responsible Party: Zambon SpA
ClinicalTrials.gov Identifier: NCT02495831     History of Changes
Other Study ID Numbers: Z7219J01
First Posted: July 13, 2015    Key Record Dates
Results First Posted: April 15, 2016
Last Update Posted: April 15, 2016
Last Verified: April 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Bioequivalence data are to be considered as a whole in all subjects (90%CI).
Keywords provided by Zambon SpA:
PK study
Additional relevant MeSH terms:
Layout table for MeSH terms
Diclofenac
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action